Message #94773 from bigbuk at Oct 25, 2001 2:57 PM
FSFI .165 BOOM ANTHRXX NEWS RUMORED
Message 16558313
__________________________________________________________
No longer a rumor.
First Scientific's Topical Antimicrobial Formula Tests Highly Effective Against
Spore Bacteria
OGDEN, Utah, Nov. 13 /PRNewswire/ -- First Scientific, Inc. (OTC: FSFI),
today announced that it has successfully completed an initial round of testing
against spore-forming bacteria that are similar to Bacillus anthracis, the
cause of the acute and often lethal disease anthrax. The testing of spore
bacterium Bacillus subtilis and Clostridium sporogenes, conducted by
independent testing firm BioScience Laboratories, indicated the company's
broad-spectrum, topical antimicrobial formula, marketed as MicrobNZ(TM),
reduced the spores by 70 to 85 percent in 15 seconds. First Scientific will
immediately begin another round of testing with a strengthened version of its
MicrobNZ-formulated handwash.
"The testing against these spore bacteria has provided us with new insight
into the already proven pathogenic capabilities of our MicrobNZ technology,"
said Randy Hales, president and CEO of First Scientific. "With some minor
modifications to the formulation we believe it may be possible to get even
better results."
The company's patent-pending MicrobNZ-formulated products have
demonstrated the highest efficacy available in the market today against all
types of pathogens. This latest round of testing against spore bacteria
continues to support the high efficacy profile of First Scientific's MicrobNZ
technology. In addition to spore bacteria, the company also intends to test
against other bioterrorism-type organisms.
First Scientific intends to seek U.S. Food and Drug Administration (FDA)
permission to add spore bacteria as an approved indication for the company's
topical antimicrobial handwash.
The MicrobNZ formulation combines the proven propensity to improve skin
condition with the lab-tested ability to effectively eliminate 99.99 percent
of a broad spectrum of pathogens*. Moreover, the antimicrobial handwash
inhibits the growth of certain pathogens for hours after use.
About First Scientific(TM):
First Scientific, Inc., (OTC: FSFI), of Ogden, Utah, is a developer and
supplier of break-through antimicrobial and skin care protective solutions for
health care, food service, and other workplace, public and home environments.
First Scientific's MicrobNZ(TM) antimicrobial technology and other skin
healing and skin care products are available through third-party distributors
and manufacturers and direct to customers under the PureCleanse(TM) product
label. First Scientific can be reached at (801) 393-5781; via email:
firstsci@firstscientific.com; or by visiting www.firstscientific.com .
This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 as well as historical information. Forward-looking
statements may involve known or unknown risks, uncertainties and other factors
that may cause the company's actual results and performance to differ
materially from the company's outlook. Important factors that could cause
actual results to differ include but are not limited to: outlook for health
care customers, demand for products, differences in anticipated and actual
product introduction dates and the ultimate success of those products in the
marketplace, among other things. Such forward-looking statements speak only
as of the date of this release. The company assumes no obligation to update
or revise any forward-looking statements. Readers are urged to carefully
review and consider the various disclosures made by the company in the
company's periodic reports on Forms 10-KSB, 10-QSB and 8-K filed with the
Securities and Exchange Commission.
First Scientific, MicrobNZ and ProCleanse are trademarks of First
Scientific, Inc. All other trademarks and registered trademarks are the
property of their respective owners.
*Editor's Note: Comprehensive in-vivo, in-vitro and moisture content test
data is available upon request.
For further information, please contact Media Relations, Melissa Clyne, PR
Mgr., +1-801-486-6763, mclyne@firstscientific.com, or Investor Relations,
Randall L. Hales, CEO, +1-801-393-5781, rhales@firstscientific.com, both of
First Scientific, Inc.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE First Scientific, Inc.
-0- 11/13/2001
/CONTACT: Media Relations, Melissa Clyne, PR Mgr., +1-801-486-6763,
mclyne@firstscientific.com, or Investor Relations, Randall L. Hales, CEO,
+1-801-393-5781, rhales@firstscientific.com, both of First Scientific, Inc. /
/Web site: firstscientific.com /
(FSFI)
CO: First Scientific, Inc.; BioScience Laboratories |
